

1 Dalmore Drive
Scoresby
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Monday, 27 November 2017

ASX RELEASE - GENERA BIOSYSTEMS LIMITED (ASX: GBI)

ANNUAL GENERAL MEETING RESULTS

The 2017 Annual General Meeting of Genera Biosystems Limited was held today in accordance with the Notice of Meeting.

In accordance with ASX Listing Rule 3.13.2, we confirm that the items of business set out in the Notice of Meeting were passed as ordinary and special resolutions on a show of hands.

As required by Section 251AA(2) of the Corporations Act 2001, the attached document details the proxy vote statistics in respect of each resolution on the agenda.

Yours faithfully,



Melanie Leydin
Company Secretary

For further information please contact:

Mr Lou Panaccio
Executive Chairman
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems:

Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. Genera has successfully developed two products to date, PapType® and RTI-Plex™, both of which are CE-IVD approved with several additional products in the company’s development pipeline.

GENERA BIOSYSTEMS LIMITED
2017 Annual General Meeting - 27 November 2017
Voting Results



The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details			Show of Hands or Poll	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type		S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain*
1.	Adoption of Remuneration Report	Ordinary	S	37,936,515	891,504	187,204	9,104,062	N/A	N/A	N/A	Carried
2.	Re-election of Mr Lou Panaccio as a Director of the Company	Ordinary	S	47,090,577	731,504	187,204	110,000	N/A	N/A	N/A	Carried
3.	Re-election of Mr David Symons as a Director of the Company	Ordinary	S	45,427,324	2,474,757	187,204	30,000	N/A	N/A	N/A	Carried
4.	Approval to Issue Options to Mezzanine Facility Lenders	Ordinary	S	29,501,820	811,497	117,204	17,688,764	N/A	N/A	N/A	Carried
5.	Approval to Issue Options to Mr Richard Hannebery (or his nominee) under Mezzanine Facility Loan	Ordinary	S	39,705,352	792,504	187,204	7,434,225	N/A	N/A	N/A	Carried
6.	Ratification of Prior Issue of Securities	Ordinary	S	47,141,940	781,504	187,204	8,637	N/A	N/A	N/A	Carried
7.	Approval to Issue 1,950,972 Options to Mr Lou Panaccio (or his nominee) in lieu of Directors fees	Ordinary	S	47,020,940	792,504	187,204	118,637	N/A	N/A	N/A	Carried
8.	Approval to Issue 1,249,372 Options to Mr Richard Hannebery (or his nominee) in lieu of Directors fees	Ordinary	S	39,705,352	792,504	187,204	7,434,225	N/A	N/A	N/A	Carried
9.	Approval to Issue 862,930 Options to Mr David Symons (or his nominee) in lieu of Directors fees	Ordinary	S	45,501,607	1,178,029	237,204	1,202,445	N/A	N/A	N/A	Carried
10.	Approval to Issue 975,486 Options to Mr Jim Kalokerinos (or his nominee) in lieu of Directors fees	Ordinary	S	46,644,911	792,504	187,204	494,666	N/A	N/A	N/A	Carried
11.	Renewal of Proportional Takeover Bid Provision in the Constitution	Special	S	46,708,052	1,224,029	187,204	-	N/A	N/A	N/A	Carried
12.	Approval of 10% Placement Facility	Special	S	47,691,857	68,853	349,938	8,637	N/A	N/A	N/A	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.